HAYWARD, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated will announce its fourth quarter and full year 2006 financial results and outlook on Tuesday, February 27, 2007, after market close.
The announcement of Kosan’s fourth quarter and full year 2006 financial results and outlook will be followed by a conference call and live webcast on February 27, 2007 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Interested parties may access the live call by dialing 866.383.8108 (US) or 617.597.5343 (international), access code 69751383.
Interested parties may listen to the webcast live at http://www.kosan.com by clicking on the “Calendar of Events” tab under the heading, “News and Events.”
The webcast is also being distributed over Thomson’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson’s individual investor center at http://www.earnings.com or by visiting any of the investor sites in Thomson’s Individual Investor Network. Institutional investors can access the call via Thomson’s password-protected event management site, StreetEvents, at http://www.streetevents.com. A telephonic replay will be available through March 6, 2007 by dialing 888.286.8010, access code: 57765410. International callers can dial 617.801.6888, access code: 57765410.
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan’s proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan’s second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-862 is currently being studied in a Phase 2 single-agent clinical trial in patients with HER2-positive metastatic breast cancer, as well as a Phase 2 combination trial with Herceptin. KOS-1584, a second candidate designed to improve pharmacokinetics, is in Phase 1 clinical trials in patients with solid tumors. Kosan’s epothilone program is partnered with Roche through a global development and commercialization agreement.
For additional information on Kosan Biosciences, please visit the company’s website at http://www.kosan.com.
NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.
Kosan Biosciences Incorporated
CONTACT: Gary S. Titus, Chief Financial Officer, +1-510-731-5373, ortitus@kosan.com, or Jane M. Green, VP, Corporate Communications,+1-510-731-5335 (office), or +1-415-652-4819 (mobile), or green@kosan.com,both of Kosan Biosciences Incorporated
Web site: http://www.kosan.com//
